Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2011 2
2012 1
2014 1
2016 1
2017 3
2018 2
2019 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M; APACT Investigators. Tempero MA, et al. J Clin Oncol. 2023 Apr 10;41(11):2007-2019. doi: 10.1200/JCO.22.01134. Epub 2022 Dec 15. J Clin Oncol. 2023. PMID: 36521097 Free PMC article. Clinical Trial.
Management of hyperbilirubinaemia in pancreatic cancer patients.
Álvarez R, Carrato A, Adeva J, Alés I, Prados S, Valladares M, Macarulla T, Muñoz A, Hidalgo M. Álvarez R, et al. Among authors: ales i. Eur J Cancer. 2018 May;94:26-36. doi: 10.1016/j.ejca.2018.01.078. Epub 2018 Mar 20. Eur J Cancer. 2018. PMID: 29505968 Review.
Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer.
Carrato A, Pazo-Cid R, Macarulla T, Gallego J, Jiménez-Fonseca P, Rivera F, Cano MT, Rodriguez-Garrote M, Pericay C, Alés I, Layos L, Graña B, Iranzo V, Gallego I, Garcia-Carbonero R, de Mena IR, Guillén-Ponce C, Aranda E. Carrato A, et al. Among authors: ales i. NEJM Evid. 2024 Feb;3(2):EVIDoa2300144. doi: 10.1056/EVIDoa2300144. Epub 2024 Jan 23. NEJM Evid. 2024. PMID: 38320486 Clinical Trial.
TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.
Benavides M, Abad A, Ales I, Carrato A, Díaz Rubio E, Gallego J, García-Foncillas J, Grávalos C, Laquente B, Pericay C, Rivera F, Tabernero J, Aranda E. Benavides M, et al. Among authors: ales i. Clin Transl Oncol. 2014 Oct;16(10):865-78. doi: 10.1007/s12094-014-1177-7. Epub 2014 Apr 12. Clin Transl Oncol. 2014. PMID: 24728654 Review.
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.
Macarulla T, Pazo-Cid R, Guillén-Ponce C, López R, Vera R, Reboredo M, Muñoz Martin A, Rivera F, Díaz Beveridge R, La Casta A, Martín Valadés J, Martínez-Galán J, Ales I, Sastre J, Perea S, Hidalgo M. Macarulla T, et al. Among authors: ales i. J Clin Oncol. 2019 Jan 20;37(3):230-238. doi: 10.1200/JCO.18.00089. Epub 2018 Dec 4. J Clin Oncol. 2019. PMID: 30523758 Clinical Trial.
Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer.
Benavides M, Alcaide-Garcia J, Torres E, Gil-Calle S, Sevilla I, Wolman R, Durán G, Álvarez M, Reyna-Fortes C, Ales I, Pereda T, Robles M, Kushnir M, Odegaard J, Faull I, Alba E. Benavides M, et al. Among authors: ales i. ESMO Open. 2022 Jun;7(3):100481. doi: 10.1016/j.esmoop.2022.100481. Epub 2022 May 4. ESMO Open. 2022. PMID: 35525184 Free PMC article.
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.
Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A. Hidalgo M, et al. Among authors: ales i. Clin Transl Oncol. 2017 Jun;19(6):667-681. doi: 10.1007/s12094-016-1594-x. Epub 2016 Dec 19. Clin Transl Oncol. 2017. PMID: 27995549 Free PMC article.
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Irigoyen A, Gallego J, Guillén Ponce C, Vera R, Iranzo V, Ales I, Arévalo S, Pisa A, Martín M, Salud A, Falcó E, Sáenz A, Manzano Mozo JL, Pulido G, Martínez Galán J, Pazo-Cid R, Rivera F, García García T, Serra O, Fernández Parra EM, Hurtado A, Gómez Reina MJ, López Gomez LJ, Martínez Ortega E, Benavides M, Aranda E; Spanish Cooperative Group of Treatment of Digestive Tumors (TTD). Irigoyen A, et al. Among authors: ales i. Eur J Cancer. 2017 Apr;75:73-82. doi: 10.1016/j.ejca.2016.12.032. Epub 2017 Mar 7. Eur J Cancer. 2017. PMID: 28222309 Clinical Trial.
15 results